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Abstract 
 
Background: The consequences of treatment for Head and Neck cancer (HNC) patients 
has profound detrimental impacts such as impaired QOL, emotional distress, delayed 
recovery and frequent use of healthcare. The aim of this trial is to determine if the 
routine use of the Patients Concerns Inventory (PCI) package in review clinics during 
the first year following treatment can improve overall quality of life, reduce the social-
emotional impact of cancer and reduce levels of distress. Furthermore, we aim to 
describe the economic costs and benefits of using the PCI. 
 
Methods: This will be a cluster preference randomised control trial with consultants 
either ‘using' or ‘not using’ the PCI package at clinic. It will involve two centres Leeds 
and Liverpool. 416 eligible patients from at least 10 consultant clusters are required to 
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 2 
show a clinically meaningful difference in the primary outcome. The primary outcome is 
the percentage of participants with less than good overall quality of life at the final one-
year clinic as measured by the University of Washington QOL questionnaire version 4 
(UWQOLv4). Secondary outcomes at one-year are the mean social-emotional subscale 
(UWQOLv4) score, Distress Thermometer (DT) score ≥4, and key health economic 
measures (QALY-EQ-5D-5L; CSRI). 
 
Discussion: This trial will provide knowledge on the effectiveness of a consultation 
intervention package based around the PCI used at routine follow-up clinics following 
treatment of head and neck cancer with curative intent. If this intervention is (cost) 
effective for patients, the next step will be to promote wider use of this approach as 
standard care in clinical practice. 
 
Trial registration: 32382. Clinical Trials Identifier, NCT03086629 
Protocol: Version 3.0, 1st July 2017. 
 
 
Keywords: Head and Neck Cancer, Patient Concerns Inventory, Quality of Life, Patient 
Reported Outcomes, Intervention. 
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Background 
The incidence of Head and neck cancer (HNC) is increasing, the three main sites being 
oral cavity (mouth), oropharynx (throat) and larynx (voice box) with about 11,000 new 
cancers in the UK each year (1). Treatments such as surgery and chemo-radiotherapy 
have a detrimental effect on basic functions including speech, swallowing and 
appearance. These in turn can have a profound negative influence on emotional well-
being and social integration (2). Patients often do not raise issues of concern in their 
follow-up consultations and it can be a challenge for clinicians to facilitate this in a busy 
clinic (3). Questionnaire prompt lists (QPL) are a means to allow patients to raise their 
agenda and help focus consultations (4,5,6,7).  The Patient Concerns Inventory (PCI-HN) 
is an item prompt list specific to head and neck cancer (8,9), and differs from many 
QPLs, which are more general cancer tools (10). The PCI-HN was designed for routine 
clinic consultations within the context of NHS financial constraints. It is freely available 
(9) and is in the early phases of development for other cancers and chronic conditions. 
The PCI consists of 56 clinical items, which patients select from before their 
appointment, to help guide the outpatient consultation through the symptoms and 
problems that they may experience following their treatment for HNC. It helps to focus 
the consultation, aid doctor-patient communication, and can assist in signposting 
patients to other professional for advice and support. 
 
The PCI supports several national initiatives and is set in the context of the national 
debate about how to bring about more person-centred care (11, 12) and the National 
Cancer Survivorship Initiative (13) which 'aims to ensure that those living with and 
beyond cancer get the care and support they need to lead as healthy and active a life as 
possible, for as long as possible'. In a survey of the British Association of Head and Neck 
Oncology Nurses (BAHNON), the PCI at that time, was the preferred assessment and the 
majority (60%) felt, as a head and neck specific tool, it was ‘most appropriate’ (14). 
 
Oncology review clinics are busy and barriers such as time constraints, a medical focus 
of the consultation, and lack of level 1 evidence of patient benefit from the use of the PCI, 
prevents its wider implementation. Although pilot work has shown that patients 
completing the PCI would like to continue to use it in clinic and that it is feasible, (15,16) 
clinicians tend to focus on traditional medical aspects. There is evidence that 
consultations can be improved through clinicians developing skills in detecting and 
responding to patient distress, thereby improving their patients' emotional functioning 
and reducing psychological distress (17,18). Preliminary findings around the PCI 
suggest that its use in clinic allows emotional issues to be discussed more openly - 
notably fears of recurrence, anxiety and depression (19,20). Hence the PCI could help 
clinician communication with patients in these important areas and consequently 
impact on how consultations are constructed.  
 
The PCI provides a process by which the patient has repeated opportunities to raise 
issues they feel are important and that they want to discuss. It can be argued that the 
routine repeated use of the PCI in follow-up clinics will benefit patients wanting support 
to speak more openly about problems or concerns e.g. psychosocial causes of symptoms; 
need for psychosocial help; to seek explanation and reassurance for more physical 
explanations about their cancer and about the side-effects of treatment. It is postulated 
that this will have a positive impact on quality of life and emotional distress and be 
demonstrable by one year following HNC treatment (21). Thus far, the majority of 
evidence related to the PCI-HN has been derived from one clinic setting. By conducting a 
randomised controlled trial (RCT) across multiple consultants, it will be possible to 
rigorously evaluate if the repeated inclusion of the PCI-HN in routine post-treatment 
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 4 
consultations does make a significant and clinically meaningfully difference in patient 
reported quality of life and distress.  
 
 
Methods/Design 
This is a preference cluster randomised control trial with consultants either ‘using or 
‘not using’ the PCI at clinic. 416 HNC eligible patients from at least 10 consultant clusters 
are required to show a clinically meaningful difference in the primary outcome, that is 
having less than good overall QOL at the final one-year clinic as measured by the 
relevant question on the UWQOL-v4 (22).  
 
Before treatment, eligible patients will be asked to consent to participation in the 
'research cohort'. Patients agree to their clinical data being used (Table 1) and to 
completing research questionnaires before each post-treatment consultation, some of 
which might be used in their consultation. Completion of all pre-consultation 
questionnaires including the PCI items will be by computer (desktop, tablet, IPAD). 
Quality Assurance is by initial training and later booster sessions for consultants and a 
post consultation survey of those in the PCI arm. Also, in the first six months of the study 
a random selection of clinic consultations will be taped in order to check how 
consultants do or do not use the PCI package. 
 
A Steering Group is guiding the research and a joint-site Management group will manage 
it. Each site will have regular Project Team meetings to review progress. Day to day 
management issues will be addressed with each unit Lead Researcher. A data manager 
(based at Aintree R&D) will have overall responsibility for ensuring data quality and 
integrity. The study will last three years comprising of set-up and piloting, 12 months of 
recruitment, 15 months of follow-up and analysis, and then write-up and initial 
dissemination. 
 
In analysis, the two patient groups will be compared after adjusting for relevant case-
mix and for effects of patients being within consultant clusters. A summary flowchart of 
the key features of this trial is shown as Figure 1.  
 
Purpose of the study and hypotheses 
The main purpose of this three-year research project is to investigate whether 
incorporating the PCI into routine head and neck cancer (HNC) follow-up consultations 
improves the overall QOL of patients. The Null hypothesis is that there is no difference 
between trial groups in the percentage of patients with less than good overall QOL at 
one year following the first baseline routine clinic post-treatment. 
 
Participant eligibility 
Eligible patients will have a first occurrence of HNC, and be treated curatively (all sites, 
stage of disease, treatments). To ensure participation of patients with little or no written 
or spoken English, translation services will be provided as necessary.  
 
Patients treated with palliative intent and patients with a history of previous HNC or 
recurrence will be excluded from the study. Although the PCI could benefit these 
patients the primary endpoint of this study is QOL at one year. For reasons of 
engagement and ethics, patients with a history of cognitive impairment, psychoses or 
dementia are excluded, as discussed and identified at the staging/treatment decision-
making Multi-Professional Team meeting (MDT). Patients who initially are included and 
treated curatively but who later start receiving treatment with palliative intent will no 
longer be asked to continue their participation in the research.   
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Method of randomisation 
Problems of consultant contamination (from switching back and forth from using to not 
using the PCI package as would be required with conventional randomisation) indicate 
this should be a cluster RCT, in that consultants are randomised to ‘using or ‘not using’ 
the PCI at all their trial clinics. The steering group approved a randomisation process 
incorporating consultant preference; a method reported previously (23). The aim is to 
limit the chance occurrence of PCI-sceptic consultants dominating the PCI group and 
PCI-enthusiastic consultants the non-PCI group. Those with a strong preference are 
offered their preferred group and those with no preference are randomised. The 
allocation process was overseen by the medical statistician involved, before any patient 
recruitment occurred. At Leeds, three of six consultants preferred to be in the PCI group, 
while the other three consultants had no preference as to group and were all allocated 
to the non-PCI control group.  At Liverpool, three of eight consultants preferred to be in 
the non-PCI control group. One of the other five consultants was randomly allocated to 
the non-PCI control group, leaving four to be in the PCI group. Thus, at the two sites, 
seven consultants were in each arm of the trial.  
 
Study intervention 
Patient completion of the PCI and its inclusion into the regular review clinic consultation 
within a summary paper output is the 'intervention' and is compared to standard out-
patient follow-up. The pre-consultation questionnaires and PCI will be used from the 
first post-treatment clinic (baseline) onwards for one year. The trial will only apply for 
routine out-patient follow-ups. Completion of all pre-consultation questionnaires and 
the PCI is by computer (desktop, tablet, IPAD). Assistance (from trained volunteers) will 
be available to patients as required. Patients of intervention consultants complete the 
PCI throughout the trial while patients of control consultants do not complete the PCI at 
all. All study patients will see their consultant surgeon at 6-8 weekly intervals for 
planned out-patient review. This might be as joint consultation with the oncologist 
depending on the configuration of the clinic.  
 
While waiting for each consultation the Intervention group patients complete the 
following: 
• Health related QOL (UW-QOLv4) 
• EQ-5D-5L  
• Distress Thermometer (DT) 
• PCI 
 
Intervention patients then take a summary paper output of their data into the clinic 
consultation (Figure 2).  Post-consultation they will be asked to complete: 
• Post-Consultation Patient Feedback about the use of the PCI. 
• Client Service Receipt Inventory (CSRI) at 6 and 12 months.  
 
The post consultation data collection will involve self-completion in clinic but either 
research assisted completion or telephone completion is possible if the patient prefers.  
 
Control patients will complete exactly the same information as intervention patients 
apart from the PCI and the post consultation feedback on the PCI. They do not take any 
summary output with them into the consultation. The summary output is a product of 
the raw inputted data from the patient being run through a software programme that 
indicates (1) all the items selected from the PCI that the patient wants to discuss (2) 
those domains from the UWQOL questionnaire for which the patient responses suggest 
a significant problem or dysfunction (using software algorithms derived from earlier 
work with the UWQOL (24), (3) the patient's overall QOL and (4) the Distress 
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 6 
Thermometer score.  The presence of this summary output during the consultation is 
the difference in reality between the intervention and control groups as far as the 
interaction between consultant and patient is concerned.  
 
Data collection and outcome measures 
Unit Clinical Trials Nurses who recruit eligible patients will keep recruitment and clinic 
attendance logs. The dedicated funded Unit researchers will collect baseline 
clinical/demographic data either via a baseline clinic questionnaire, with demographic 
questions chosen as far as possible to match those included in the head and neck 5000 
project (25), or by extraction from baseline clinical records. Baseline data will include 
cancer site, disease severity, HPV status, treatment details, gender, age, deprivation 
[IMD from post code], smoking, alcohol, and ACE-27 comorbidity.  All clinical outcome 
data will be collected automatically via IPAD at each consultation. A data manager 
(based at Aintree) will have overall responsibility for ensuring data quality and 
integrity.   
 
Primary outcome measure 
The primary outcome measure is overall QOL, specifically the percentage with less than 
good overall QOL at the final one-year clinic as measured by the single UWQOL-v4 
question (22). The anticipated result in the control group is 30%. The UW-QOLv4 is a 
commonly used HNC specific HRQOL questionnaire (26, 27) and has been used with 
HNC patients at the Aintree Regional Head and Neck Unit since 1995. Over 1000 
patients have completed over 5000 UW-QOL questionnaires giving the research team 
considerable experience in analysing and reporting this QOL measure. 
 
Secondary outcome measures 
1. Mean social-emotional subscale score of UW-QOL 
The Aintree Research team was involved in developing the UW-QOL subscales, and the 
social-emotional subscale (24) is the mean of 6 domain scores (each 0-100) - anxiety, 
mood, pain, activity, recreation and shoulder function. The anticipated result in the 
control group is a mean score of 75.  
 
2. Distress Thermometer (DT) score of 4 or more (range 0 to 10). The anticipated result 
in the control group is 34%. The Distress Thermometer (DT) is a single item self-report 
measure and has been used to screen for distress in various cancers (28-31). A score of 
four and above denotes significant distress as this correlates with optimal sensitivity 
and specificity to the Hospital Anxiety Depression Scale (29, 32). 
 
Cost-effectiveness 
1. Quality-adjusted life year (QALY) 
Quality-adjusted life year (QALY) is used as a summary measure of health benefit for 
economic evaluation, using the EQ-5D-5L health index to adjust for patient QOL (33, 34). 
QALY is used as a common unit to allow comparisons across different interventions or 
disease areas (35). EQ-5D-5L is a validated generic, health-related, preference-based 
measure comprising mobility, self-care, usual activities, pain and discomfort, anxiety 
and depression. These are complemented by a visual analogue scale (VAS) (36), on 
which patients are asked to indicate their current health from 0 (worst imaginable 
health) to 100 (best imaginable health) (37).  
 
2. Health service use and costs 
Health service use by participating patients will be collected using a Client Service 
Receipt Inventory (CSRI). CSRI is a form that is usually administered in an interview 
setting or by self-completion via postal surveys or at clinics – asking them to recall 
retrospectively the type and frequency of their contacts with primary and secondary 
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 7 
care NHS services. A CSRI form adapted to the study was developed using existing CSRIs, 
available from the DIRUM open access database (38), as a reference and guidance with 
input from study researchers. For this trial, services such as physiotherapist, 
occupational therapist, social worker and others are included. To translate the service 
use into costs, unit costs from published sources will be applied to the patients’ self-
reported service use data and the mean total cost of care per patient over 12 months 
will be calculated in each group. CSRI is the most common means of collecting service 
use data, usually with a short recall period of up to 6 months (39, 40), in health 
economics studies that require data across a range of health care settings. CSRIs were 
developed first in the field of mental health economics (41), and a review of their use is 
published by Ridyard and Hughes (42). 
 
6. Cost of the PCI intervention 
Resources and materials use for the delivery of the PCI intervention will be recorded 
and costed and the total cost of the PCI intervention will be calculated. 
 
Sample size calculation 
We have used nearly 20 years of accumulated experience with the UW-QOL to estimate 
a sample size that is pragmatic enough for a trial to be doable, yet able to detect 
meaningful differences if they exist. In regard to all UWQOL records collected the 
percentages of patients reporting less than good overall quality of life were relatively 
similar over different time periods from diagnosis and the expectation for the trial 
control group was taken as 30% after about 12 months.  Cluster randomized trials 
require larger sample sizes than the individually randomised design because 
observations on individuals in the same cluster tend to be correlated, thereby reducing 
the effective sample size. The degree of correlation within consultant clusters, as 
estimated by the intra-class correlation (ICC) was estimated as barely above zero (6.7e-
05) for consultants at Aintree. Assuming a likely control group outcome of 30%, an ICC 
value of 0.01 for the trial and not wishing to miss a halving in outcome rate, then a total 
of 312 patients from at least 10 consultants were required. After factoring a likely loss of 
15% through patient mortality during the follow-up period and a possible maximum 
loss of 10% from initial non-consent, this then implied a total of 416 eligible patients 
needing to be approached for participation to the research.  This number would also 
detect a moderate-sized clinical difference of 10 units (75 Vs. 85) in the mean composite 
social-emotional subscale score, for which an ICC estimate of 0.025 was obtained for 
consultants within Aintree. Data from an MD project with 325 HNC patients at Aintree 
gave an estimated 34% with a Distress Thermometer score ≥4, and the trial numbers 
would be sufficient to detect a halving in this outcome.  
 
 
Statistical analysis 
As inference will target the individual patient level, analyses will need to adjust for 
potential clustering in the data. We will report results for each group (PCI, non-PCI) and 
the estimated effect size from the use of PCI and its precision (95% confidence interval). 
For the primary outcome, we will report the intra-cluster correlation coefficient to 
assess the amount of clustering. In reporting results, we will follow the CONSORT 
statement extension applicable to cluster RCTs. We will use random effects (multi-level) 
logistic regression methods and will estimate the effect of PCI after making adjustment 
for relevant case-mix and for clustering effects of patients being within consultant 
clusters. Only baseline patient factors will be considered as case-mix adjusters and these 
include age, gender, treatment, overall clinical stage, tumour site and baseline clinic 
assessment of whether overall UWQOL was less than good (Y/N). A P value ≤0.05 is 
considered statistically significant.  Secondary clinical outcomes will be analysed as per 
protocol.  
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We will fully cost the delivery of the PCI intervention and associated costs such as 
training and other materials used. We will use published national average NHS 
reference consultant costs, accounting for overheads. From an NHS perspective, we will 
undertake a primary cost-effectiveness analysis of the PCI approach, using the change in 
% of patients with ‘less than good’ overall QOL between baseline and one-year as the 
outcome effect, and a subsequent cost-utility analysis using QALY as the outcome effect 
measured using the EQ-5D-5L questionnaire. Costs of service use and QALY data will be 
derived from the CSRI and EQ-5D-5L questionnaires collected at baseline, 3, 6, 9 and 12 
months. The area under the curve method will be used to calculate QALYs, weighting 
survival by QOL weights obtained from the EQ-5D-5L. We will compare our findings 
with unofficial NICE thresholds (ceilings) of £20,000 to £30,000 per QALY. Discounting 
is unnecessary given the time period. We will account for patient clustering, producing 
cost-effectiveness planes and acceptability curves (CEACs) to convey to policy makers 
the probability that PCI approach is cost-effective at different payer thresholds. We will 
undertake 5,000 bootstrapped replications to generate confidence intervals around 
point estimates. The CSRI also allows us to account for the impact on healthcare service 
use from intervention participation, important when further rolling out the PCI 
approach. 
 
Quality Assurance (QA) 
Quality Assurance will be ensured by initial training and booster sessions for 
consultants, together with post consultation patient feedback and audio taping of a 
number of consultations. 
 
Training 
There will be a short training programme for staff using the PCI before any patient 
recruitment. A brief manual/instruction booklet is used to talk through how the PCI 
should be used in consultations. There will also be two refresher sessions at 4 and 8 
months into the trial recruitment phase. 
 
Patients completing the PCI will be asked to complete a post-consultation feedback on 
paper identified by unique study number and date of clinic; they will be asked to leave 
this in clinic with the research team; telephone completion of this will also be available. 
The question is: Did the doctor make reference to the PCI prompt list during the 
consultation? Response options are 'Not at all', 'A little', 'Somewhat', 'A great deal'.  
Any 'Not at all' response will be followed through with the relevant consultant with a 
view to resolving the issue for future clinics conducted. 
 
Fidelity 
In the first months of the study a random selection of clinic consultations will be taped. 
The additional burden of taping is an argument for focusing on the set-up period in 
order to check how consultants do or do not use the PCI. The tapes will allow a check on 
if and how the PCI print out is being used and it will allow for a check for contamination 
in the non-PCI group. It would be expected that between 3-6 months into the study, two 
clinics from each consultant would be taped.  
 
Management and Governance 
The trial will be guided by the Steering Group, meeting during the set-up and six-
monthly thereafter to ensure progress towards reaching the study’s purpose and to give 
oversight regarding research governance. Its' membership includes an independent 
chairman, at least two other independent members, the two Unit Lead Investigators, 
Trial Coordinator (Full Time), Research Practitioner (Part-Time), Medical Statistician, 
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Health Economist, IT/data management representation and a patient representative 
from each Unit.  
 
There will be joint-Unit management group meetings every three months, membership 
comprising the two Unit Lead Investigators, dedicated funded researchers, IT/data 
management representation and a patient representative from each Unit. Statistical and 
Economic representation as required. Within Unit, there will be monthly Project Team 
meetings, membership comprising Unit Lead investigator, dedicated funded 
researchers, Clinical Trials Nurse(s), and patient representative. Day to day 
management issues will be addressed by Unit Researchers and escalate to the Unit Lead 
Investigator. 
 
 
Discussion  
 
There is growing evidence that enhanced symptom monitoring during routine cancer 
care using patient-reported outcomes benefits patients in respect to HRQOL and 
survival (43). The premise of this trial is that the PCI can be integrated into routine 
clinical consultations with minimal cost implication as the doctor-patient interaction 
will be more time efficient and facilitate appropriate and targeted multi-professional 
referrals. The item prompt list approach of the PCI should have direct benefit for the 
participants. A key issue limiting successful implementation of patient reported 
outcomes in clinical practice is clinicians' lack of knowledge on how to effectively utilise 
PROs data in their clinical encounters (44). Hence, for this trial there is an educational 
component and training around the use of the PCI. Also, the patient feedback and 
analysis of taped consultations will help underpin the evidence related to use of the PCI 
in the consultation. From this material, it would be possible in the future to develop a 
more robust training package, informed from the lessons learnt from this trial.  In 
addition, the need for clear system guidelines built into how to most effectively use the 
PCI for the clinician, the patient and other members of the multi-professional team is 
recognised (45). The findings from this trial will inform the development of a PCI 
manual both for patients and professionals. 
 
The collection of the data in both arms of the trial by touch screen computer-assisted 
technology (IPAD) has distinct advantages in terms of data capture. With advances in 
digital health it could be expected that this approach would become regularly employed. 
Touch screen health-related QOL data collection can be used for scientific 
documentation as well as in clinical settings (46). For the purpose of the trial the 
computer system has been transferred from Aintree to the other sites. This has not been 
as straightforward as expected. This has caused delays in the use of the IPADs in the 
other clinics. After completion of this trial, in order to support wider adoption of the PCI 
approach to patient care, progress is being made in respect to a cloud based platform 
which should be more readily accessible and easier to use than the current system.  
 
The use of the PCI is a form of intervention in clinic by the consultant. There are other 
intervention trials that focus to improve function and wellbeing in patients with head 
and neck cancer. Hansson and colleagues (47) compare a person-centred care 
intervention in terms of health-related quality of life, disease-specific symptoms or 
problems, with traditional care as a control group for patients with head and neck 
cancer. Another trial by van der Hout and co-workers (48) is testing the efficacy, cost-
utility and reach of an eHealth self-management application 'Oncokompas' to obtain 
optimal supportive care. Both trials explore different tools in a different context to the 
PCI in this trial. There are many different ways to help enable patients to recover from 
head and neck cancer, and the possibility of having several evidence based interventions 
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can only help to improve patient’s outcomes and allow centres to select the most 
appropriate intervention with their healthcare environment. This study has QOL as the 
primary outcome. This reflects the importance QOL has in terms of outcome following 
HNC. Also, given the inherent difficulties in QOL evaluation, such as adaptation, response 
shift, limitations in questionnaire wording, scaling and scoring, it demonstrates the 
potential power of the PCI to impact positively in patient care. A positive finding from 
this research will not only serve to promote wider use of the PCI in HNC, but also 
accelerate the development, piloting and introduction of the PCI in other cancers and 
chronic conditions. Level 1 evidence as to the benefits of the PCI in HNC care will help 
drive up standards of care. This research will add substantially to the evidence 
supporting the use of question prompt lists in NHS practice.  
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Figure Legends 
Figure 1: Patient Flow Diagram 
Figure 2: Example of PCI printouts 
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Table 1: Schedule for collecting  Clinical and Demographic  details 
 
 
Timepoint Trial Period 
 Enrolment Baseline Clinic Follow Up Clinics 
Gender X   
DOB X   
IMD 2015 X   
Smoking and Drinking Details  X X* 
Living Situation  X  
Employment   X  
Income  X  
Primary Diagnosis (ICD code)  X   
Tumour Site X   
Treatment Plan X   
Ethnicity  X   
TNM Stage    
Cancer Staging X   
Histology (SNOMED) X   
HPV Status X   
Co-Morbidity X   
ACE 27 X   
    
*  Completion at patient 6 and 12 month study visit 
 
Table Click here to download Table Table.docx 
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After study starts: New patients identified at MDT are approached to participate in research cohort. 
Patients agree to their clinical data being used in the trial as well as completing research questionnaires 
prior to and after their consultations post-treatment some of which might be used in their consultation.  
 
 
 
 
Before study starts:  All consultants participating in the study are randomly allocated to PCI or NON-PCI. 
Consultants who will use the PCI will receive training. 
 
 
 
Patient declines 
First post-treatment clinic and then 
subsequent planned review clinics  
 
 
UW-QOL, EDT and EQ-5D VAS 
 
 
END OF FOLLOW-UP (one year following first post-treatment consultation) 
First post-treatment clinic and then 
subsequent planned review clinics  
 
 
 
Patient checked for eligibility and approached by trial nurse 
Patient re-contacted after a 1 
week consideration window 
Patient Consents 
Data collected pre-consultation: 
 Health related QOL (UW-QOLv4) 
 EQ-5D-5L 
 Distress Thermometer (DT) 
Data collected post-consultation: 
 Client Service Receipt Inventory (CSRI) (6 
and 12 months) 
 
 
Baseline patient/clinical case-mix data collected. 
 
 
Patients take a summary paper copy of their PCI 
into the consultation.  
 
 
 
UW-QOL, EDT and EQ-5D VAS 
 
 
Patient 
Excluded 
Patient 
Enrolled 
 
Clinical and 
patient 
characterist
ics  
Consultants using PCI Consultants not using PCI 
Loss to follow-up at each clinic 
Data collected pre-consultation: 
 Health related QOL (UW-QOLv4) 
 EQ-5D-5L 
 Distress Thermometer (DT) 
 PCI 
Data collected post-consultation: 
 Client Service Receipt Inventory (CSRI) (6 
and 12 months) 
 Post-consultation feedback 
 
 
Figure Click here to download Figure Figures1 Patient flow
diagram.docx
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Figure Click here to download Figure Figures2 example of PCI
printouts.docx
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